Active Ingredient(s):Niraparib FDA Approved: * March 27, 2017 Pharm Company: *TESARO INC Category:Cancer
Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.
The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, ...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion